Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report-Reference-Cited by-同舟云学术

Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report

Published:2022-01 Issue: Volume:36 Page:039463202211153
ISSN:0394-6320
Container-title:International Journal of Immunopathology and Pharmacology
language:en
Short-container-title:Int J Immunopathol Pharmacol

Author:

Montolio-Chiva Lydia¹^ORCID,Carmona-Talavera Diego²,López-Ortega Jose M²,Orenes-Vera Ana V¹,Flores-Fernández Eduardo¹,Alegre-Sancho Juan J¹

Affiliation:

1. Department of Rheumatology, Doctor Peset University Hospital, Valencia, Spain

2. Autoimmunity Laboratory, Doctor Peset University Hospital, Valencia, Spain

Abstract

In the diagnostic of systemic sclerosis (SSc), both anti-centromere (ACA) and anti-topoisomerase I (ATA) antibodies are considered mutually exclusive, though their coexistence has been also reported in some patients. Notably, nintedanib has been approved for the treatment of interstitial lung disease associated to SSc. Herein, we present the clinical case of a 41-year-old woman with SSc who shows an immunological seroconversion (from ACA positivity to a coexistence of ACA and ATA antibodies) together with changes in her clinical phenotype. Besides, the patient responds positively to the treatment of her lung involvement with a combination of immunomodulators and antifibrotic agents.

Publisher

SAGE Publications

Subject

Pharmacology,Immunology,Immunology and Allergy,Pharmacology,Immunology,Immunology and Allergy

Link

http://journals.sagepub.com/doi/pdf/10.1177/03946320221115310

Reference11 articles.

1. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis

2. Bibliographical Study of the Concurrent Existence of Anticentromere and Antitopoisomerase I Antibodies

3. Concomitância de autoanticorpos na esclerose sistêmica: como interpretar?

4. Are ACA and Scl 70 antibodies mutually exclusive?